Select AD - Cortical Disarray Measurement (CDM) Technology
From Pharma/Biotech
Using CDM® we will optimise patient selection, combine other clinical and patient demographics, and positively impact trial costs and performance. CDM® can estimate a patient’s pathology disease stage using grey matter quality. We provide a likelihood that a patient will progress to the next stage of disease within the next few years.
-
Most popular related searches
Clinical
Unlocking novel insights for doctors from MRI scans enables earlier diagnoses and more personalised treatment, giving hope to patients suffering from neurodegenerative diseases. Visualising brain changes using CDM® can support communication between doctors, patients and their carers to help them understand the situation.
We are tackling uncertainty in diagnosing neurodegenerative conditions, by giving clinicians confidence, and patients a better understanding of their condition. Cortical Disarray Measurement (CDM®) software has been granted Breakthrough Device designation by the FDA.
We enable differential diagnoses by mapping neurodegenerative disease progression across different regions of the brain, revealing different disease patterns based on cell structure. CDM® has identified different patterns of neurodegeneration in the brain in atypical Alzheimer’s disease (posterior cortical atrophy) and fronto-temporal dementia.
Our insight into the micro-structure of the brain, can help clinicians track and accurately predict the course or decline of neurodegenerative disease. CDM® measures are designed to detect altered quality of grey matter in AD patients. Our research into MCI also supports using (CDM®) for identification of the early stages of Alzheimer’s disease.
Identifying and tracking changes based on the brain’s cellular structure enables clinicians to offer personalised treatment and actively promote brain health throughout a lifetime. Our technology can be rapidly applied across multiple neurodegenerative, neuropsychiatric, and neurodevelopmental diseases.
Customer reviews
No reviews were found for Select AD - Cortical Disarray Measurement (CDM) Technology. Be the first to review!